Sugi Predict

Sugi Predict / Compounds / SCHEMBL6683006

SCHEMBL6683006

SCHEMBL6683006

Nc1c(Br)cccc1S(N)(=O)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 14/20 0.64
▸ CA1 P00915 11/20 0.64
▸ CA4 P22748 4/20 0.64
▸ CA6 P23280 3/20 0.64
▸ CA9 Q16790 9/20 0.52
▸ CA12 O43570 4/20 0.52
▸ CA7 P43166 3/20 0.52
▸ CA5A P35218 3/20 0.52
▸ CA5B Q9Y2D0 2/20 0.52
▸ CA14 Q9ULX7 2/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CDK2 P24941 1/20 0.45
▸ PLCG1 P19174 1/20 0.43
▸ CA3 P07451 1/20 0.41
▸ APEX1 P27695 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ STAT3 P40763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL456613 0.83 CA2 (0.48) CA2CA1CA4CA6CA9
SCHEMBL29878430 0.83 CA2 (0.48) CA2CA1CA4CA6CA9
SCHEMBL528641 0.79 CA2 (0.67) CA2CA1CA4CA6CA9
SCHEMBL7761041 0.79 CA2 (0.67) CA2CA1CA4CA6CA9
SCHEMBL30630011 0.78 CA2 (1.00) CA2CA1CA4CA6CA9
SCHEMBL344271 0.78 CA2 (1.00) CA2CA1CA4CA6CA9
SCHEMBL635927 0.77 CDK2 (0.61) CA2CA1CA4CA6CA9
SCHEMBL11647231 0.77 CA1 (0.52) CA2CA1CA4CA6CA9
SCHEMBL10415325 0.76 CA2 (0.95) CA2CA1CA4CA6CA9
Potassium SCHEMBL10415326 0.76 CA2 (0.95) CA2CA1CA4CA6CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 — — CN disclosed
US-11912659-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2024-02-27 — — US disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 — — EP disclosed
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
CN-105934425-B EBNA1 inhibitors and methods of use thereof 威斯塔解剖学和生物学研究所 2020-08-07 — — CN disclosed
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2020-06-11 — — US disclosed
US-10421718-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-09-24 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
WO-2016210234-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 — — WO disclosed
WO-2016206101-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 — — WO disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed
WO-2004052312-A2 ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-06-24 — — WO disclosed
CN-1293665-A New compounds and their use as positive AMPA receptor modulators NEUROSEARCH AS (DK) 2001-05-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CA2 3767/4885CA1 3628/4885CA4 2835/4885
US-11242317-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CA2 3767/4885CA1 3628/4885CA4 2835/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 CA2 3935/4885CA1 3665/4885CA4 2834/4885
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML CA2 3767/4885CA1 3628/4885CA4 2835/4885
US-10421718-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CA2 3767/4885CA1 3628/4885CA4 2835/4885
US-11912659-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 CA2 3851/4885CA1 3154/4885CA4 3003/4885
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use EBNA1BP2, MLLT1, PML CA2 3767/4885CA1 3628/4885CA4 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.